DGX Quest Diagnostics Inc stock chart & analysis
Conviction 47HealthcareScan · Fri, Nov 6, 2026Quest Diagnostics Inc (DGX) closed at $255.63 (+0.35%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 67, RS Rating 91, -1.3% from its 52-week high, +47.3% year to date. Sector: Healthcare · Services-Medical Laboratories.
Financials as of Wed, Sep 30, 2026 · quarterly.
DGX technical analysis
Trend
DGX is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 6.8% above the 50-day ($239.37) and 19.6% above the 200-day ($213.79). ADX(14) at 17 points to a weak trend — more range than direction. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 67, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 91 puts its weighted 12-month performance ahead of about 91% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 0.9× its 20-day average. It trades about $245.0M a day on average. ATR(14) is $6.59, 2.6% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.26) shows accumulation.
Key levels
The chart pattern's support is $224.64 and its resistance $252.92. The 52-week range is $171.18 to $259.00; price is 1.3% below the high and 49.3% above the low. The VWAP anchored at the 52-week high is $255.07, below price.
Performance
DGX returned +1.5% (1 week), +10.7% (1 month), +7.6% (3 months), +36.4% (6 months), +43.4% (1 year), +47.3% (year to date).
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Services-Medical Laboratories · Listed 1996 · 57,000 employees
Congress activity
Disclosed STOCK Act trades in DGX · 8 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Carol Devine Miller house · R · WV · traded 2025-03-10 | Sell | $15K–$50K | 2025-03-10 | 2026-08-13 | |
 Julie Johnson house · D · TX · traded 2025-10-30 | Sell | $1K–$15K | 2025-10-30 | 2026-08-05 | |
 Alan Armstrong senate · R · OK · traded 2026-03-30 | Buy | $1K–$15K | 2026-03-30 | 2026-07-21 | |
Alan Armstrong senate · R · OK · traded 2026-03-27 | Buy | $1K–$15K | 2026-03-27 | 2026-07-21 | |
RK Rohit Khanna house · CA | Other | — | — | 2026-03-09 | |
 Julia Letlow house · LA · traded 2025-07-24 | Sell | $1K–$15K | 2025-07-24 | 2025-08-11 | |
Carol Devine Miller house · R · WV · traded 2025-03-10 | Sell | $1K–$15K | 2025-03-10 | 2025-04-11 | |
 Thomas H Tuberville senate · traded 2024-01-03 | Sell | $15K–$50K | 2024-01-03 | 2024-02-14 |
Insider activity
SEC Form 4 transactions in DGX · open-market 7 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
DELANEY MARK E SVP & Chief Commercial Officer · Common Stock · 2026-11-03 | Grant | 2.62K | — | 2026-11-03 | 2026-11-05 |
Doherty Catherine T. Executive Vice President · Common Stock · 2026-11-03 | Grant | 4.83K | — | 2026-11-03 | 2026-11-05 |
Doherty Catherine T. Executive Vice President · Common Stock · 2026-11-03 | Exercise | 22.11K | $2.7M | 2026-11-03 | 2026-11-05 |
Doherty Catherine T. Executive Vice President · Common Stock · 2026-11-03 | Sell | 3.82K | $937K | 2026-11-03 | 2026-11-05 |
Doherty Catherine T. Executive Vice President · Common Stock · 2026-11-03 | Sell | 5.99K | $1.5M | 2026-11-03 | 2026-11-05 |
Doherty Catherine T. Executive Vice President · Common Stock · 2026-11-03 | Sell | 1.15K | $284K | 2026-11-03 | 2026-11-05 |
Doherty Catherine T. Executive Vice President · Common Stock · 2026-11-03 | Sell | 2.36K | $586K | 2026-11-03 | 2026-11-05 |
Doherty Catherine T. Executive Vice President · Common Stock · 2026-11-03 | Sell | 3K | $749K | 2026-11-03 | 2026-11-05 |
Doherty Catherine T. Executive Vice President · Common Stock · 2026-11-03 | Sell | 2.88K | $721K | 2026-11-03 | 2026-11-05 |
Doherty Catherine T. Executive Vice President · Common Stock · 2026-11-03 | Sell | 2.91K | $730K | 2026-11-03 | 2026-11-05 |
SEC filings
EDGAR filings in DGX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.